Reasons for using and efficacy of raltegravir in salvage regimens without protease inhibitors in clinical practice

The efficacy of raltegravir (RAL) in salvage regimens without protease inhibitors (PI) has not been evaluated in randomized trials, and information about its efficacy and reasons for its initiation in cohort studies has received scant attention. In some particular scenarios physicians may be forced to use RAL without PI due to advanced protease resistance, toxicity or patient refusal. Supplement: Abstracts of the Tenth International Congress on Drug Therapy in HIV Infection http://www.biomedcentral.com/content/pdf/1758-2652-13-S4-info.pdf Conference: Tenth International Congress on Drug Therapy in HIV Infection 7-11 November 2010 Glasgow, UK (Published: 8 November 2010) doi:10.1186/1758-2652-13-S4-P35 Cite this article as: Llibre et al.: Reasons for using and efficacy of raltegravir in salvage regimens without protease inhibitors in clinical practice. Journal of the International AIDS Society 2010 13(Suppl 4):P35. Full text: PubMed Central: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113037/